The MHRA in the UK has begun a rolling review of Moderna's new coronavirus vaccine

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has begun a rolling review of Moderna's mRNA-based COVID-19 vaccine mRNA-1273, meaning the MHRA will conduct an independent assessment of Moderna's vaccine.
Moderna's mRNA vaccine (pictured: ) last week, Moderna completed the registration of its Phase 3 clinical trial mRNA-1273 in 30,000 participants.
, 25,654 participants were now vaccinated for the second time in the Phase 3 COVE study, according to the company.
The National Institutes of Health (NIH) launched the COVE study in July, as Moderna's COVID-19 vaccine entered Phase 3 clinical studies in record time.
of the first phase of the study, mRNA-1273, showed that participants receiving two doses of the vaccine had a rapid and strong immune response to SARS-CoV-2. Tal Zaks, chief medical officer of
Moderna, said: "Phase 1 data demonstrate that mRNA-1273 vaccines produce a strong immune response at all dose levels and clearly select 100 sg as the optimal dose in the initial exemption and strengthening programme.
development of mRNA-1273 is under way in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), which the U.S. government has selected as operation Warp Speed.